PHÂN TÍCH CHI PHÍ HIỆU QUẢ CỦA ROSUVASTATIN SO VỚI ATORVASTATIN TRONG ĐIỀU TRỊ RỐI LOẠN LIPID MÁU TẠI VIỆT NAM

Abstract

Background: Hypercholesterolemia is one of the most important modifiable risk factors for cardiovascular disease prevention. Treatment of dyslipidemia requires a combination of lifestyle changes and medication. Therefore, this study focused on evaluating the cost-effectiveness of using rosuvastatin compared with atorvastatin in the treatment of dyslipidemia in Vietnam. Methodology: Study using a decision tree model, comparing the cost-effectiveness between the use of rosuvastatin and atorvastatin in the treatment of dyslipidemia. The duration of treatment was calculated from drug administration until the target LDL-C was reached. Data are taken from a literature review of documents based on databases. The model's evaluation timeframe is one year. Cycles are calculated per cycle of reaching the LDL-C goal. Results: Rosuvastatin has better clinical efficacy than atorvastatin in the treatment of dyslipidemia. From the health insurance point of view, in the treatment of hyperlipidemia, rosuvastatin dominates both in terms of cost savings and increased treatment effectiveness. Specifically, when treated with rosuvastatin, it saved nearly 34.5 million VND per unit of added efficiency.. Results of one-way sensitivity analysis and propabilistic sensitivity analysis defined in most cases, rosuvastatin is dominant compared to atorvastatin. Conclusion: Rosuvastatin has both better clinical efficacy and lower cost of treatment than atorvastatin by helping patients better reach their target LDL-C levels. Research is limited as the input data are based on literature reviews.